Bevacizumab in Treating Patients With Angiosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

June 6, 2013

Study Completion Date

November 10, 2016

Conditions
Sarcoma
Interventions
BIOLOGICAL

Bevacizumab

Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).

Trial Locations (5)

19140

Fox Chase Cancer Center CCOP Research Base, Philadelphia

55905

Mayo Clinic Cancer Center, Rochester

92093-0658

Rebecca and John Moores UCSD Cancer Center, La Jolla

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Northwestern University

OTHER